New Delhi, Jan 2 || Adaptive cardiac devices are revolutionising heart disease treatment for real-time monitoring and dynamic therapy adjustments, according to a report.
The report by GlobalData, a data and analytics company, showed that these devices offer continuous, precise interventions enabling better patient outcomes. These also present a shift toward more effective and responsive management of heart disease.
In contrast to traditional devices like pacemakers that deliver consistent outputs, the novel adaptive cardiac technologies leverage artificial intelligence (AI) to analyse heart activity. The adaptive technology also adjusts treatment based on fluctuations in cardiac rhythms, leading to a personalised approach.
This ensures that therapy aligns precisely with a patient's evolving condition, providing 24/7 care and better health outcomes.
According to GlobalData forecast, the cardiovascular devices market is expected to grow at a compound annual growth rate (CAGR) of 5.20 per cent from $84.8 billion in 2023 to $140 billion in 2033.
This growth highlights the increasing demand for advanced diagnostic and therapeutic tools tailored to cardiac care.